Platform & Strategies

Oncology Strategy

HomePlatform & StrategiesOncology Strategy

Next Generation of PD-1/L1 based BsAb to Overcome Limitations of Conventional PD-1/L1 Therapy & Provide More Effective Therapies

MOA of conventional PD-1/L1 therapy

MOA of conventional PD-1/L1 therapy
MOA of conventional PD-1/L1 therapy

PD-1/L1 Therapy Resistance and Enhancing Immunotherapy

PD-1/L1 Therapy Resistance and Enhancing Immunotherapy
PD-1/L1 Therapy Resistance and Enhancing Immunotherapy

Summary: ABL’s Modular, ‘Plug-N-Play’ Grabody™ Platform

Summary: ABL’s Modular, ‘Plug-N-Play’ Grabody™ Platform
Summary: ABL’s Modular, ‘Plug-N-Play’ Grabody™ Platform